吉西他滨、多西他赛、卡培他滨、顺铂二线治疗 FOLFIRINOX 后晚期胰腺癌的安全性和疗效。
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.
机构信息
Department of Medical Oncology, Center GF Leclerc, Dijon, France.
Research Platform in Biological Oncology, Dijon, France.
出版信息
Anticancer Res. 2020 Jul;40(7):4011-4015. doi: 10.21873/anticanres.14395.
BACKGROUND/AIM: The aim of this monocentric study was to evaluate the efficacy and tolerability of a polychemotherapy regimen based on gemcitabine, docetaxel, capecitabine, cisplatin (PDGX) as second-line for advanced pancreatic cancer after FOLFIRINOX.
PATIENTS AND METHODS
Patients received FOLFIRINOX as first-line regimen were retrospectively identified between January 2016 and January 2019. After disease progression or unacceptable toxicity, patients eligible for second-line therapy were treated in our center by PDGX.
RESULTS
During this period, 18 patients received PDGX regimen as second-line therapy. Main grade 3 toxicities were hematologic, which required dose adaptation in 14/18 patients. No toxic death was observed. Median second-line progression-free survival (PFS) and overall survival (OS) were 2,91 and 5,3 months, respectively. Total OS from the initiation of first-line was and 11,9 months.
CONCLUSION
Second-line PDGX regimen after FOLFIRINOX failure is feasible, with notable toxicity profile and is associated with poor clinical outcomes.
背景/目的：本单中心研究旨在评估吉西他滨、多西他赛、卡培他滨、顺铂（PDGX）联合化疗方案作为 FOLFIRINOX 后晚期胰腺癌二线治疗的疗效和耐受性。
患者与方法
回顾性分析 2016 年 1 月至 2019 年 1 月期间接受 FOLFIRINOX 一线治疗的患者。疾病进展或不可接受的毒性后，符合二线治疗条件的患者在我院接受 PDGX 治疗。
结果
在此期间，18 例患者接受 PDGX 二线治疗。主要的 3 级毒性为血液学毒性，需要对 14/18 例患者进行剂量调整。未观察到毒性死亡。二线无进展生存期（PFS）和总生存期（OS）的中位数分别为 2.91 和 5.3 个月。从一线治疗开始的总 OS 为 11.9 个月。
结论
FOLFIRINOX 失败后二线 PDGX 方案是可行的，具有显著的毒性特征，与较差的临床结局相关。
Zotero 插件